NEW YORK, NY, USA I August 01, 2025 I Spine BioPharma, Inc. announced today the Phase 3 MODEL trial (MOderate – Severe Degenerative Disc Disease Evaluation of the Lumbar Spine) evaluating SB-01, a TGF ...

– Treatment with the selective NaV1.8 pain signal inhibitor VX-993 after bunionectomy surgery did not meet the primary endpoint – – Treatment with VX-993 was generally safe and well tolerated, with ...

BOLOGNA, Italy I July 28, 2025 I Alfasigma S.p.A today announced positive topline results from the OLINGUITO Phase 3 clinical trial (NCT05785611; Eudra CT 2022-501354-10-01), i evaluating filgotinib ...

- New preclinical data for the PBGENE-DMD final clinical candidate demonstrates an increase in dystrophin positive muscle cells across key muscle types, ...

SAN DIEGO, CA, USA I July 21, 2025 I Epirium Bio Inc. (Epirium), a clinical-stage biopharmaceutical company advancing medicines for neuromuscular and fibrotic diseases, today announced the completion ...

PRINCETON, NJ, USA I July 18, 2025 I Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 INDEPENDENCE trial evaluating Reblozyl® (luspatercept-aamt) with concomitant janus kinase inhibitor ...

Full B Cell Depletion Achieved in Blood, Spleen, and Lymph Nodes in Non-Human Primate Study Data Supports the Nomination of OTX-201, a Novel In Vivo CAR-T Therapy, as Orbital’s First Product Candidate ...

July 15, 2025 I Otsuka Pharmaceutical Co., Ltd. (Otsuka) has entered into an asset purchase agreement with Cantargia AB (Cantargia) for the acquisition of assets related to CAN10. CAN10 is an IL-1RAP ...

– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms – STAMFORD, ...

HONG KONG, China I July 28, 2025 I Akeso, Inc. (9926.HK) (“Akeso” or the “Company”) is pleased to announce that the National Medical Products Administration (NMPA) has accepted the supplementary New ...

LONDON, UK I July 28, 2025 I GSK plc (LSE/NYSE: GSK) today announced it has entered into agreements with Hengrui Pharma (600276.SH; 01276.HK) to develop up to 12 innovative medicines, adding ...

HONG KONG, China I July 15, 2025 I Akeso, Inc. (9926.HK) (“Akeso” or the “Company”) is pleased to announce that the first patient has been successfully enrolled in the registration Phase III clinical ...